CD8A and melanoma: We observed that therapeutic α-PD-1 binding to Vδ1 (β = −0.065, P = 0.044, HR = 0.94 with 95% CI of 0.88–1) and CD8 (β = −0.24, P = 0.036, HR = 0.78 with 95% CI of 0.62–0.98) T cells was associated with significantly longer progression-free survival in patients with melanoma.